Dr. Zeidner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
170 University of NC
Trlr Cb
Chapel Hill, NC 27599Phone+1 732-236-3903
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014- Johns Hopkins UniversityResidency, Internal Medicine, 2008 - 2011
New York Medical CollegeClass of 2008
Certifications & Licensure
NC State Medical License 2014 - 2025
MD State Medical License 2011 - 2015- American Board of Internal Medicine Medical Oncology
Clinical Trials
- High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Start of enrollment: 2016 Aug 22
- A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS Start of enrollment: 2018 Aug 29
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Start of enrollment: 2022 Aug 24
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.Joseph F Mort, David Brighton, Samantha DiBenedetto, Leah Wells, Stephen M Clark
European Journal of Haematology. 2024-11-27 - 3 citationsRisk prediction for clonal cytopenia: multicenter real-world evidence.Zhuoer Xie, Rami Komrokji, Najla Al Ali, Alexandra Regelson, Susan Geyer
Blood. 2024-11-07 - Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters
Blood. 2024-11-01
Journal Articles
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
Abstracts/Posters
- OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid LeukemiaJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)Joshua Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid TumorsJoshua F Zeidner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual MeetingDecember 9th, 2024- Syndax Announces Additional Positive Data for Revuforj® (Revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialDecember 9th, 2024
- QTc Formula Affects Heart Rhythm Assessment, Chemotherapy DoseSeptember 30th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
